122 related articles for article (PubMed ID: 35031189)
1. Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.
Musa FB; Brouwer E; Ting J; Schwartz NRM; Surinach A; Bloudek L; Ramsey SD
Gynecol Oncol; 2022 Mar; 164(3):645-650. PubMed ID: 35031189
[TBL] [Abstract][Full Text] [Related]
2. Patterns of care and health care resource use among Medicaid-enrolled women with recurrent or metastatic cervical cancer.
Leath CA; Nysenbaum J; Ting J; Zhang YJ; Fiori A; Pauly N
J Manag Care Spec Pharm; 2023 May; 29(5):490-498. PubMed ID: 37121257
[No Abstract] [Full Text] [Related]
3. Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis.
Alholm Z; Monk BJ; Ting J; Pulgar S; Boyd M; Sudharshan L; Bains S; Nicacio L; Coleman RL
Gynecol Oncol; 2021 May; 161(2):422-428. PubMed ID: 33741208
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER-Medicare study.
Shao C; He J; Kachroo S; Jin F
Cancer Med; 2019 Dec; 8(18):7613-7622. PubMed ID: 31668011
[TBL] [Abstract][Full Text] [Related]
5. Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy.
Johnston S; Wilson K; Varker H; Malangone-Monaco E; Juneau P; Riehle E; Satram-Hoang S; Sommer N; Ogale S
Clin Colorectal Cancer; 2017 Dec; 16(4):386-396.e1. PubMed ID: 28619608
[TBL] [Abstract][Full Text] [Related]
6. Health Care Resource Utilization and Total Costs of Care for Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia in the United States: A Retrospective Claims Analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Dalton D; Epstein J; Snider JT; DuVall AS
Clin Ther; 2024 Jan; 46(1):3-11. PubMed ID: 37981560
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy treatments, costs of care, and survival for elderly patients diagnosed with cervical cancer: an observational study.
Shao C; He J; Stein K; Keefe S
Curr Med Res Opin; 2020 Jul; 36(7):1187-1194. PubMed ID: 32314603
[No Abstract] [Full Text] [Related]
8. Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis.
Ito D; Feng C; Fu C; Kim C; Wu J; Epstein J; Snider JT; DuVall AS
Expert Rev Pharmacoecon Outcomes Res; 2023; 23(7):773-787. PubMed ID: 37278284
[TBL] [Abstract][Full Text] [Related]
9. Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies.
Purdum A; Tieu R; Reddy SR; Broder MS
Oncologist; 2019 Sep; 24(9):1229-1236. PubMed ID: 30850561
[TBL] [Abstract][Full Text] [Related]
10. Real-world utilization and outcomes of systemic therapy among patients with advanced or recurrent endometrial cancer in the United States.
Liu J; Emond B; Maiese EM; Lafeuille MH; Lefebvre P; Ghelerter I; Wu C; Hurteau JA; Thaker PH
Curr Med Res Opin; 2022 Nov; 38(11):1935-1945. PubMed ID: 35975577
[TBL] [Abstract][Full Text] [Related]
11. Healthcare Costs in Men with Metastatic Castration-Resistant Prostate Cancer: An Analysis of US Medicare Fee-For-Service Claims.
Freedland SJ; Davis MR; Epstein AJ; Arondekar B; Ivanova JI
Adv Ther; 2023 Oct; 40(10):4480-4492. PubMed ID: 37531024
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
Sonawane K; Castellano T; Washington C; Ting J; Surinach A; Kirshner C; Chhatwal J; Ayer T; Moore K
Gynecol Oncol Rep; 2022 Dec; 44(Suppl 1):101101. PubMed ID: 36506039
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis.
Sonawane K; Castellano T; Washington C; Ting J; Surinach A; Kirshner C; Chhatwal J; Ayer T; Moore K
Gynecol Oncol Rep; 2022 Dec; 44():101121. PubMed ID: 36589508
[TBL] [Abstract][Full Text] [Related]
14. Economic burden of multiple myeloma among patients in successive lines of therapy in the United States.
MacEwan JP; Batt K; Yin W; Peneva D; Sison S; Vine S; Chen C
Leuk Lymphoma; 2018 Apr; 59(4):941-949. PubMed ID: 28805105
[TBL] [Abstract][Full Text] [Related]
15. Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA.
Barzi A; Lin F; Song J; Lam C; Nie X; Noman A; Kwong WJ
Drugs Real World Outcomes; 2023 Sep; 10(3):395-404. PubMed ID: 37540381
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting.
Nadler E; Espirito JL; Pavilack M; Boyd M; Vergara-Silva A; Fernandes A
Clin Lung Cancer; 2018 Jul; 19(4):360-370. PubMed ID: 29576407
[TBL] [Abstract][Full Text] [Related]
18. Real-world Treatment Patterns and Clinical Outcomes Across Lines of Therapy in Patients With Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer.
Le DT; Ott PA; Korytowsky B; Le H; Le TK; Zhang Y; Maglinte GA; Abraham P; Patel D; Shangguan T; Chau I
Clin Colorectal Cancer; 2020 Mar; 19(1):32-38.e3. PubMed ID: 31813769
[TBL] [Abstract][Full Text] [Related]
19. Beyond Frontline Therapy with Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer: A Real-World US Study.
Shore ND; Ionescu-Ittu R; Laliberté F; Yang L; Lejeune D; Yu L; Duh MS; Mahendran M; Kim J; Ghate SR
Clin Genitourin Cancer; 2021 Dec; 19(6):480-490. PubMed ID: 34373223
[TBL] [Abstract][Full Text] [Related]
20. Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States.
Zhang X; Beachler DC; Masters E; Liu F; Yang M; Dinh J; Jamal-Allial A; Kolitsopoulos F; Lamy FX
J Manag Care Spec Pharm; 2022 Feb; 28(2):255-265. PubMed ID: 34854733
[No Abstract] [Full Text] [Related]
[Next] [New Search]
